Technical Analysis for HOWL - Werewolf Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| 20 DMA Support | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 19 hours ago |
| 60 Minute Opening Range Breakdown | about 20 hours ago |
| Possible NR7 | about 20 hours ago |
| 1.5x Volume Pace | about 23 hours ago |
| Down 3% | about 23 hours ago |
Get a Trading Assistant
- Earnings date: 05/08/2024
Werewolf Therapeutics, Inc. Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Solid Tumors Health Sciences Treatment Of Cancer Cancer Immunotherapy Lymphoma Hematologic Malignancies Advanced Solid Tumors Metastatic Solid Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.1939 |
| 52 Week Low | 1.66 |
| Average Volume | 676,932 |
| 200-Day Moving Average | 4.01 |
| 50-Day Moving Average | 2.28 |
| 20-Day Moving Average | 2.45 |
| 10-Day Moving Average | 2.93 |
| Average True Range | 0.31 |
| RSI (14) | 50.00 |
| ADX | 28.26 |
| +DI | 29.37 |
| -DI | 18.77 |
| Chandelier Exit (Long, 3 ATRs) | 3.24 |
| Chandelier Exit (Short, 3 ATRs) | 2.75 |
| Upper Bollinger Bands | 3.54 |
| Lower Bollinger Band | 1.36 |
| Percent B (%b) | 0.51 |
| BandWidth | 89.16 |
| MACD Line | 0.16 |
| MACD Signal Line | 0.18 |
| MACD Histogram | -0.0138 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.71 | ||||
| Resistance 3 (R3) | 2.72 | 2.65 | 2.67 | ||
| Resistance 2 (R2) | 2.65 | 2.59 | 2.65 | 2.66 | |
| Resistance 1 (R1) | 2.57 | 2.56 | 2.53 | 2.56 | 2.65 |
| Pivot Point | 2.50 | 2.50 | 2.48 | 2.49 | 2.50 |
| Support 1 (S1) | 2.41 | 2.44 | 2.38 | 2.40 | 2.31 |
| Support 2 (S2) | 2.34 | 2.40 | 2.34 | 2.30 | |
| Support 3 (S3) | 2.26 | 2.34 | 2.29 | ||
| Support 4 (S4) | 2.25 |
